Τρίτη 1 Αυγούστου 2017

Treating ER+ Breast Cancer with CDK4/6 Inhibitors [News in Brief]

Data from the MONARCH2, PALOMA-1, and TREnd trials strongly support using CDK4/6 inhibitors alongside standard endocrine therapy for advanced ER-positive breast cancer. Including these targeted agents not only improves progression-free survival but may reverse acquired resistance to hormone treatment.



http://ift.tt/2w1slLJ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου